DOI: 10.1055/s-00000097

Deutsche Zeitschrift für Onkologie

LinksClose Window

References

Cortes J, Cescon DW, Rugo HS. et al.
KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Lancet 2020;
396: 1817-1828

Download Bibliographical Data

Access:
Access:

We do not assume any responsibility for the contents of the web pages of other providers.